Literature DB >> 17935125

A small interfering RNA targeting proteinase-activated receptor-2 is effective in suppression of tumor growth in a Panc1 xenograft model.

Kentaro Iwaki1, Kohei Shibata, Masayuki Ohta, Yuichi Endo, Hiroki Uchida, Masayuki Tominaga, Ryoki Okunaga, Seiichiro Kai, Seigo Kitano.   

Abstract

Proteinase-activated receptor-2 (PAR-2), which is a G protein-coupled receptor, is activated in inflammatory processes and cell proliferation. We previously demonstrated that an anti-PAR-2 antibody suppresses proliferation of human pancreatic cells in vitro. However, there have been no studies of PAR-2 signaling pathways in vivo. The aim of this study was to determine whether blockade of PAR-2 by RNA interference influences pancreatic tumor growth. We originally constructed small interfering RNAs (siRNAs) targeting human PAR-2, and performed cell proliferation assays of Panc1 human pancreatic cancer cell line with these siRNAs. Intratumoral treatment with these PAR-2 siRNAs and atelocollagen was also performed in a xenograft model with nude mice and Panc1 cells. siRNAs against human PAR-2 inhibited proliferation of Panc1 cells, whereas control scramble siRNAs had no effect on proliferation. The PAR-2 siRNAs dramatically suppressed tumor growth in the xenograft model. PAR-2-specific siRNA inhibited growth of human pancreatic cancer cells both in vitro and in vivo. Blockade of PAR-2 signaling by siRNA may be a novel strategy to treat pancreatic cancer. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17935125     DOI: 10.1002/ijc.23123

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.

Authors:  Lizhi He; Alistair Ingram; Adrian P Rybak; Damu Tang
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

2.  Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110).

Authors:  J Y Suen; G D Barry; R J Lohman; M A Halili; A J Cotterell; G T Le; D P Fairlie
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Serum deprivation induces glucose response and intercellular coupling in human pancreatic adenocarcinoma PANC-1 cells.

Authors:  Sahar Hiram-Bab; Yuval Shapira; Marvin C Gershengorn; Yoram Oron
Journal:  Pancreas       Date:  2012-03       Impact factor: 3.327

4.  Proteinase-activated receptor 2 promotes TGF-β-dependent cell motility in pancreatic cancer cells by sustaining expression of the TGF-β type I receptor ALK5.

Authors:  Franziska Zeeh; David Witte; Thomas Gädeken; Bernhard H Rauch; Evelin Grage-Griebenow; Nadja Leinung; Sofie Joline Fromm; Stephanie Stölting; Koichiro Mihara; Roland Kaufmann; Utz Settmacher; Hendrik Lehnert; Morley D Hollenberg; Hendrik Ungefroren
Journal:  Oncotarget       Date:  2016-07-05

Review 5.  Proteinase-Activated Receptor 2 Is a Novel Regulator of TGF-β Signaling in Pancreatic Cancer.

Authors:  David Witte; Franziska Zeeh; Thomas Gädeken; Frank Gieseler; Bernhard H Rauch; Utz Settmacher; Roland Kaufmann; Hendrik Lehnert; Hendrik Ungefroren
Journal:  J Clin Med       Date:  2016-11-30       Impact factor: 4.241

Review 6.  Proteinase-Activated Receptor 2 May Drive Cancer Progression by Facilitating TGF-β Signaling.

Authors:  Hendrik Ungefroren; David Witte; Bernhard H Rauch; Utz Settmacher; Hendrik Lehnert; Frank Gieseler; Roland Kaufmann
Journal:  Int J Mol Sci       Date:  2017-11-22       Impact factor: 5.923

Review 7.  Signaling Crosstalk of TGF-β/ALK5 and PAR2/PAR1: A Complex Regulatory Network Controlling Fibrosis and Cancer.

Authors:  Hendrik Ungefroren; Frank Gieseler; Roland Kaufmann; Utz Settmacher; Hendrik Lehnert; Bernhard H Rauch
Journal:  Int J Mol Sci       Date:  2018-05-24       Impact factor: 5.923

8.  Atelocollagen-mediated in vivo siRNA transfection in ovarian carcinoma is influenced by tumor site, siRNA target and administration route.

Authors:  Matthieu Meryet-Figuière; Charlotte Lecerf; Emilie Varin; Jean-Luc Coll; Marie-Hélène Louis; Soizic Dutoit; Florence Giffard; Cécile Blanc-Fournier; Siham Hedir; Nicolas Vigneron; Emilie Brotin; Laurent Pelletier; Véronique Josserand; Christophe Denoyelle; Laurent Poulain
Journal:  Oncol Rep       Date:  2017-08-04       Impact factor: 3.906

Review 9.  RNA interference technologies and therapeutics: from basic research to products.

Authors:  Marta López-Fraga; Tamara Martínez; Ana Jiménez
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.